Bear Stearns Healthcare Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
Medtronic: Purchase of rapid-exchange stent-delivery technology from Johnson & Johnson is possible if the Federal Trade Commission requires J&J to sell the technology before completing its acquisition of Guidant. "Would we be interested? Yes...for the right price," Medtronic CFO Gary Ellis acknowledged at the Bear Stearns Healthcare Conference in New York Sept. 12. As conditions of approval for the acquisition, the European Commission and Canadian Competition Bureau are already requiring J&J to divest some businesses in their respective markets (1"The Gray Sheet" Sept. 5, 2005, In Brief). FTC is expected to rule on the proposed acquisition in October...
You may also be interested in...
J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes
Abbott could be a strong player in the drug-eluting stent market by 2007 if the J&J/Guidant merger is completed as required by FTC
J&J divests guidewires In Canada
Johnson & Johnson/Cordis will sell its steerable guidewire business in Canada in response to concerns raised by the Canadian Competition Bureau (CCB) in its review of the company's proposed $24 bil. acquisition of Guidant, J&J announced Sept. 2. CCB is not formally requiring J&J to divest the business as a condition of approving the merger, but said that it is concerned the merger will make the steerable guidewire market uncompetitive and that it will continue to monitor the markets affected by the merger for three years, as provided under Canada's Competition Act. The firm was also asked to divest certain European businesses as a condition of EC approval of the acquisition. The U.S. Federal Trade Commission's decision is expected in October (1"The Gray Sheet" Aug. 29, 2005, p. 13)...
Ocular Sciences Acquisition Puts Ciba, J&J/Vistakon In Cooper’s Sights
Cooper Companies' planned Ocular Sciences purchase positions the firm to achieve $1 bil. in annual contact lens sales by 2007, according to CEO Thomas Bender